ARTICLE | Clinical News
Alfacell reports Phase III data
May 23, 2000 7:00 AM UTC
ACEL said that preliminary results of a 154-patient Phase III trial of its Onconase ribonuclease agent in patients with unresectable malignant mesothelioma showed a median survival time of 7.7 months ...